Galecto (GLTO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 18, 2025, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by June 17, 2025.
Voting matters and shareholder proposals
Election of two directors: Carl Goldfischer, M.D. and David Shapiro, M.D., both recommended by the board.
Approval sought for issuance of common stock upon conversion of Series A Preferred Stock, in line with Nasdaq Listing Rule 5635(a).
Ratification of EY Godkendt Revisionspartnerselskab as independent auditor for fiscal year ending December 31, 2025.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board recommends all proposals, including director nominees and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Galecto
- Cash position of $535M supports pipeline progress; net loss driven by R&D acquisition costs.GLTO
Q4 202520 Mar 2026 - Damora advances potent CALR-targeted therapies for ET and MF, aiming for broad clinical impact.GLTO
Leerink Global Healthcare Conference 20269 Mar 2026 - Key proposals include stock conversion, capital increase, redomestication, and new equity plans.GLTO
Proxy Filing31 Dec 2025 - BRM-1420, a dual ENL-YEATS/FLT3 inhibitor, advances toward clinical trials for high-risk AML.GLTO
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202524 Dec 2025 - Shareholders will vote on key proposals to support growth, redomestication, and new equity plans.GLTO
Proxy Filing16 Dec 2025 - Advancing preclinical antibody and small molecule therapies for blood cancers after major PIPE raise.GLTO
Registration Filing16 Dec 2025 - Annual meeting to vote on director elections, stock issuance, and auditor ratification.GLTO
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, stock conversion, auditor, and review governance and compensation.GLTO
Proxy Filing2 Dec 2025 - Acquisition expands blood cancer pipeline and secures $285M funding for clinical milestones through 2029.GLTO
M&A Announcement17 Nov 2025